USD 285.3 Billion
Report ID:
SQMIG35I2354 |
Region:
Global |
Published Date: November, 2024
Pages:
174
|Tables:
64
|Figures:
70
Immunotherapy Drugs Market size was valued at USD 285.3 Billion in 2023 and is poised to grow from USD 328.95 Billion in 2024 to USD 891.12 Billion by 2032, growing at a CAGR of 15.3% during the forecast period (2025-2032).
The growth of the market is driven by rising prevalence of chronic illnesses globally. According to the International Diabetes Federation, it is estimated that 537 million adults in the age group of 20-79 years would be suffering from diabetes in 2021. Further, the number was predicted to surge to 783 million by 2045. Major companies operating in the market are focusing on new product findings and strategic collaborations to advance research studies regarding immunotherapy drugs. COVID-19 had a positive effect on the immunotherapy market due to the increase in demand for drugs associated with immunotherapy. For instance, an article featured in Open Forum Infection Diseases in January 2021 stated that treatment with monoclonal antibodies was most predicted effects in preventing the need for additional hospital or emergency department medical care among high-risk ambulatory individuals with early COVID-19 and that it was well-tolerated. Furthermore, the regulatory authorities' increased number of immunotherapy product approvals was also expected to accelerate market growth. Some of the factors contributing to the growth of immunotherapy drugs market include growing acceptance of targeted treatment over traditional treatment, introduction of biosimilars, lifestyle disorders, and increasing demand for monoclonal antibodies. In addition, other contributing factors to this growth include an increase in the number of collaborations, research laboratories, and direct and indirect investments in R&D by biotechnology and pharmaceutical companies, boosting the market.
Market snapshot - 2025-2032
Global Market Size
USD 285.3 Billion
Largest Segment
Monoclonal Antibodies
Fastest Growth
Vaccines
Growth Rate
15.3% CAGR
To get more reports on the above market click here to Buy The Report
Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Cancer generated the largest revenue share of about 91.10% in 2023 because of the introduction of cancer immunotherapies and rise in the incidence of cancer. According to Globocan 2020, breast cancer and lung cancer are the two most prevalent forms with a prevalence of about 11.7% and 11.4%, respectively. In April 2021, the market was further stirred up following the FDA's approval of Opdivo (nivolumab) for treatment in stomach cancer patients in combination with chemotherapy. These factors are expected to continue to drive the market, as the incidence of cancer is growing and developments in immunotherapies are advancing.
As more patients have several types of autoimmune diseases globally, and due to the local approvals of immunotherapy drugs in various geographies, Autoimmune Disorders Segment is expected to grow at the fastest growth rate during the forecast period. According to a research study from NCBI, 0.46% of people are believed to suffer from rheumatoid arthritis across the globe. For instance, regional approvals boost expansion: In February 2022, China's National Medical Products Administration cleared GSK's Benlysta (belimumab) for active lupus nephritis. As autoimmune disease knowledge and diagnosis continue to improve, this market is set to grow rapidly, offering opportunity for the producers of immunotherapies.
Owing to growing R&D of therapeutic monoclonal antibodies, along with favorable government initiatives, the segment of monoclonal antibodies captured the largest share in 2023 with over 76.30%. This is due to the rise in diseases that are targeted for treatment using monoclonal antibodies, including various autoimmune disorders and several cancers. A recent instance of growing interest in monoclonal antibodies includes the acceptance by the U.S. FDA in May 2022 of the supplementary Biologics License Application for the priority review of Dupixent, dupilumab, for the treatment of prurigo nodularis. Government initiatives and support for funding in biotechnology-related research have rapidly enhanced the growth of this market.
During the forecast period, the vaccines segment is expected to grow at the fastest growth on account of growing clinical trial activity and strategic deals amongst the key players involved in vaccine development. This can be attributed to the increasing focus on prevention of infectious diseases, along with the development of new technologies. This includes mRNA-based vaccinations. For instance, Pfizer Inc. entered into a strategic collaboration agreement with BioNTech SE focused on the development of an mRNA-based vaccine preventing shingles. In addition, growing investments in vaccines-related research are highlighted by the fact that in March 2022, the National Institutes of Health announced the start of the Phase 1 study of three experimental HIV mRNA-based vaccines. Such aspects are likely to drive segmental growth for vaccines.
To get detailed analysis on other segments, Request For Free Sample Report
North America, with the largest share, headed the immunotherapy drugs market in 2023. The high acceptance rate of immunotherapy treatments, presence of key pharmaceutical companies, and favorable reimbursement policies are the primary factors for its leading position in the region. Due to the high prevalence of autoimmune diseases and cancer in the US and Canada, immunotherapies are in high demand. The presence of established research institutes and a proper healthcare system in this region accelerates the development and commercialization process of the immunotherapy drugs. Therefore, North America remains an attractive market for the companies that manufacture drugs on immunotherapy as most of them are considering this region for launching their product or commercializing it.
During the forecast period, the immunotherapy medicine market is projected to show its fastest growth in Asia-Pacific. This growth is attributed to increasing healthcare costs, a rising burden of autoimmune diseases and cancers, and improved infrastructure. Major markets, such as China, Japan, and India, are relatively large in terms of the patient population and have an emerging need for efficient therapies. Government endeavors and investments in research on biotechnology are further boosting the growth of the immunotherapy medications market in the region. Due to this, the development of immunotherapy drugs has a huge number of opportunities in Asia-Pacific. Many companies are expanding their presence in the region through strategies such as alliances, joint ventures, and market expansion.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Prevalence of Chronic Diseases
Advancing Research and Development
High Development Cost and Complexity
Regulatory Challenges and Uncertainty
Request Free Customization of this report to help us to meet your business objectives.
The leading companies are focusing on growth strategies such as product enhancements, approvals of new products, and acquisitions to drive up their market shares. Sanofi and Kymab entered into an agreement in January 2021. Under this agreement, Sanofi would acquire Kymab for approximately USD 1.1 billion upfront. This added a monoclonal antibody, KY1005, to the pipeline.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest Analysis, the growth of the immunotherapy drugs market is the result of increasing incidence of chronic diseases, enhancements in R&D, and due to new developments, such as combination treatments and personalized immunotherapy. Despite the high development costs and regulatory uncertainties posing challenges, the business is expected to grow at a very rapid pace offering new therapeutic options for patients affected by cancer, autoimmune diseases, and infectious diseases. New products and methods for unmet medical needs are bound to change the face of the market as research in immunotherapy continues to open new paths. The future of the market of immunotherapy drugs is substantial, and it may ensure considerable improvement of human health.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 285.3 Billion |
Market size value in 2032 | USD 891.12 Billion |
Growth Rate | 15.3% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Immunotherapy Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Immunotherapy Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Immunotherapy Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Immunotherapy Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Immunotherapy Drugs Market size was valued at USD 285.3 Billion in 2023 and is poised to grow from USD 328.95 Billion in 2024 to USD 891.12 Billion by 2032, growing at a CAGR of 15.3% during the forecast period (2025-2032).
Merck & Co., Inc. (United States) ', 'Johnson & Johnson Services, Inc. (United States) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'AstraZeneca (United Kingdom) ', 'Pfizer Inc. (United States) ', 'Amgen Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Eli Lilly and Company (United States) ', 'Sanofi (France) ', 'Bristol-Myers Squibb Company (United States) ', 'Gilead Sciences, Inc. (United States) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'AbbVie Inc. (United States) ', 'GSK PLC (United Kingdom) ', 'Immunocore Holdings Plc (United Kingdom) ', 'Astellas Pharma Inc. (Japan) ', 'Genmab A/S (Denmark) ', 'MacroGenics, Inc. (United States) ', 'Ferring BV (Switzerland)'
The increasing prevalence of chronic diseases, such as cancer, autoimmune diseases, and infectious diseases, has a severe effect on the immunotherapy pharmaceuticals market. As the population ages and lifestyles become different, there are increased demands for effective treatments. Immunotherapies can present potential cures, and their wider utilization is predicted to drive the growth of the market. The main factor that propels the demand for immunotherapy medications today is the increasing prevalence of chronic diseases, coupled with better awareness and diagnosis.
Personalized Immunotherapy: With recent advances in precision medicine, genomics, and genetic engineering, the market is witnessing a surge in demand for personalized immunotherapy. This practice mainly deals with drug design based on each genetic make-up, history of diseases, and specific characteristics of his immune system. Trials conducted with personalized immunotherapies have shown many promising results: enhanced efficacy, reduced side effects. Business is investing heavily in the development of personalized immunotherapies, and this trend is predicted to continue to drive market growth and change the paradigm for the treatment of many diseases, such as autoimmune diseases and cancers.
North America, with the largest share, headed the immunotherapy drugs market in 2023. The high acceptance rate of immunotherapy treatments, presence of key pharmaceutical companies, and favorable reimbursement policies are the primary factors for its leading position in the region. Due to the high prevalence of autoimmune diseases and cancer in the US and Canada, immunotherapies are in high demand. The presence of established research institutes and a proper healthcare system in this region accelerates the development and commercialization process of the immunotherapy drugs. Therefore, North America remains an attractive market for the companies that manufacture drugs on immunotherapy as most of them are considering this region for launching their product or commercializing it.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35I2354
[email protected]
USA +1 351-333-4748